Results 21 to 30 of about 89,572 (287)

Docetaxel suppressed cell proliferation through Smad3/HIF-1α-mediated glycolysis in prostate cancer cells

open access: yesCell Communication and Signaling, 2022
Background Tumor glycolysis is a critical event for tumor progression. Docetaxel is widely used as a first-line drug for chemotherapy and shown to have a survival advantage.
Junming Peng   +6 more
doaj   +1 more source

Study of the Effect of Linoleic Acid on the Expression Level of MicroRNA-106b and MicroRNA-20a and their Related Target MHC Class I Chain-related Protein A in Docetaxel-treated Gastric Cancer Cells [PDF]

open access: yesMiddle East Journal of Cancer, 2021
Background: MicroRNAs are involved in response to therapeutic agents and have the ability to regulate the expression level of the targets associated with cancer growth and progression.
Najibeh Shekari   +6 more
doaj   +1 more source

The key cellular senescence related molecule RRM2 regulates prostate cancer progression and resistance to docetaxel treatment

open access: yesCell & Bioscience, 2023
Background Prostate cancer is a leading cause of cancer-related deaths among men worldwide. Docetaxel chemotherapy has proven effective in improving overall survival in patients with castration-resistant prostate cancer (CRPC), but drug resistance ...
Bisheng Cheng   +11 more
doaj   +1 more source

Transcription factor network analysis based on single cell RNA-seq identifies that Trichostatin-a reverses docetaxel resistance in prostate Cancer

open access: yesBMC Cancer, 2021
Background Overcoming drug resistance is critical for increasing the survival rate of prostate cancer (PCa). Docetaxel is the first cytotoxic chemotherapeutical approved for treatment of PCa.
Patricia M. Schnepp   +7 more
doaj   +1 more source

Nanocrystal-Loaded Micelles for the Enhanced In Vivo Circulation of Docetaxel

open access: yesMolecules, 2021
Prolonging in vivo circulation has proved to be an efficient route for enhancing the therapeutic effect of rapidly metabolized drugs. In this study, we aimed to construct a nanocrystal-loaded micelles delivery system to enhance the blood circulation of ...
Meng Cheng   +8 more
doaj   +1 more source

High efficacy and low toxicity of weekly docetaxel given as first-line treatment for metastatic breast cancer [PDF]

open access: yes, 2005
Background: Docetaxel is one of the most effective antitumor agents currently available for the treatment of metastatic breast cancer (MBC). This phase II multicenter study prospectively analyzed the efficacy and toxicity of docetaxel given on a weekly ...
Abenhardt, Wolfgang   +29 more
core   +1 more source

Prospective Multicenter Randomized Phase III Study of Weekly versus Standard Docetaxel (D2) for First-Line Treatment of Metastatic Breast Cancer [PDF]

open access: yes, 2010
Purpose: Previous phase II studies have indicated a greatly reduced hematotoxicity of docetaxel-based regimens administered on weekly schedules. The present trial was initiated to randomly compare the toxicity and efficacy of weekly docetaxel versus its ...
Abenhardt, Wolfgang   +21 more
core   +1 more source

Docetaxel versus active symptom control for refractory oesophagogastric adenocarcinoma (COUGAR-02) : an open-label, phase 3 randomised controlled trial [PDF]

open access: yes, 2008
Background: Second-line chemotherapy for patients with oesophagogastric adenocarcinoma refractory to platinum and fluoropyrimidines has not shown benefits in health-related quality of life (HRQoL). We assessed whether the addition of docetaxel to active
Cliona C Kirwan (10530920)   +847 more
core   +1 more source

Efficacy and Prognostic Factors of Docetaxel Rechallenge on Metastatic Castration-resistant Prostate Cancer Patients

open access: yesZhongliu Fangzhi Yanjiu, 2019
Objective To assess the efficacy of docetaxel rechallenge on castration-resistant prostate cancer (mCRPC) patients and to analyze prognostic factors. Methods We retrospectively reviewed the medical history of 120 mCRPC patients treated with the first ...
DUAN Liqun   +4 more
doaj   +1 more source

Prospective, open, multi-centre phase I/II trial to assess safety and efficacy of neoadjuvant radiochemotherapy with docetaxel and oxaliplatin in patients with adenocarcinoma of the oesophagogastric junction [PDF]

open access: yes, 2013
Background: This phase I/II-trial assessed the dose-limiting toxicities (DLT) and maximum tolerated dose (MTD) of neoadjuvant radiochemotherapy (RCT) with docetaxel and oxaliplatin in patients with locally advanced adenocarcinoma of the oesophagogastric ...
Klautke, Gunther   +12 more
core   +1 more source

Home - About - Disclaimer - Privacy